Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

BTK Cys481Ser drives ibrutinib resistance via ERK1/2 and protects BTK wild-type MYD88-mutated cells by a paracrine mechanism

Blood (2018) 131 (18): 2047–2059.

https://doi.org/10.1182/blood-2017-10-811752

Published: 2018

Includes: Supplemental data

Journal Articles

The Genomic Landscape of MYD88 Wild-Type WaldenströM's Macroglobulinemia Ischaracterized By Somatic Mutations in TBL1XR1, the CBM Complex, and NFKB2

Zachary Hunter, PhD, Nickolas Tsakmaklis, BA, Maria Demos, BS, Amanda Kofides, BS, Lian Xu, Gloria Chan, MS, Jiaji Chen, BS, Manit Munshi, MS, Xia Liu, MD, Joshua Gustine, Christopher Patterson, MAcc, Toni Dubeau, NP, Patricia Severns, NP, Jorge J. Castillo, MD, Guang Yang, PhD, Steven P Treon, MDPhDFRCP

Blood (2017) 130 (Supplement 1): 4011.

https://doi.org/10.1182/blood.V130.Suppl_1.4011.4011

Published: 2017

Journal Articles

Patient-Reported Symptoms during Ibrutinib Holds: A Withdrawal Syndrome

Jorge J. Castillo, MD, Joshua Gustine, Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Steven P Treon, MDPhDFRCP

Blood (2017) 130 (Supplement 1): 4058.

https://doi.org/10.1182/blood.V130.Suppl_1.4058.4058

Published: 2017

Journal Articles

Ibrutinib Discontinuation in Waldenström Macroglobulinemia: Etiologies, Outcomes, and IgM Rebound

Joshua Gustine, Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Lian Xu, Zachary Hunter, PhD, Steven P Treon, MDPhDFRCP, Jorge J. Castillo, MD

Blood (2017) 130 (Supplement 1): 802.

https://doi.org/10.1182/blood.V130.Suppl_1.802.802

Published: 2017

Journal Articles

Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial

Steven P Treon, MDPhDFRCP, Kirsten Meid, MPH, Joshua Gustine, Kurt S. Bantilan, MPH, Toni Dubeau, NP, Patricia Severns, NP, Guang Yang, PhD, Lian Xu, Christopher Patterson, MAcc, Irene M Ghobrial, MD, Jacob Laubach, MD, Zachary Hunter, PhD, Jorge J. Castillo, MD, Maria L. Palomba, MD, Ranjana H. Advani, MD

Blood (2017) 130 (Supplement 1): 2766.

https://doi.org/10.1182/blood.V130.Suppl_1.2766.2766

Published: 2017

Journal Articles

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

Blood (2017) 130 (Supplement 1): 2767.

https://doi.org/10.1182/blood.V130.Suppl_1.2767.2767

Published: 2017

Journal Articles

Long-Term Follow-up of a Prospective Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in Waldenstrom's Macroglobulinemia

Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Joshua Gustine, Irene M Ghobrial, MD, Jorge J. Castillo, MD, Steven P Treon, MDPhDFRCP

Blood (2017) 130 (Supplement 1): 2772.

https://doi.org/10.1182/blood.V130.Suppl_1.2772.2772

Published: 2017

Journal Articles

TP53 mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström Macroglobulinemia

Joshua Gustine, Kirsten Meid, MPH, Patricia Severns, NP, Toni Dubeau, NP, Nickolas Tsakmaklis, BA, Christopher Patterson, MAcc, Guang Yang, PhD, Xia Liu, MD, Maria Demos, BS, Amanda Kofides, BS, Jiaji Chen, BS, Manit Munshi, MS, Maria Luisa Guerrera, MD, Gloria Chan, MS, Jorge J. Castillo, MD, Zachary Hunter, PhD, Steven P Treon, MDPhDFRCP, Lian Xu

Blood (2017) 130 (Supplement 1): 5140.

https://doi.org/10.1182/blood.V130.Suppl_1.5140.5140

Published: 2017

Journal Articles

Abnormal Splicing Patterns and Novel Intron Retentions Affect Genes Regulating Splicing, NF-Kb, ERK1/2, and TP53 in Waldenstrom's Macroglobulinemia

Zachary Hunter, PhD, Nickolas Tsakmaklis, BA, Lian Xu, Maria Demos, BS, Amanda Kofides, BS, Jiaji Chen, BS, Gloria Chan, MS, Manit Munshi, MS, Xia Liu, MD, Joshua Gustine, Kirsten Meid, MPH, Christopher Patterson, MAcc, Toni Dubeau, NP, Patricia Severns, NP, Jorge J. Castillo, MD, Guang Yang, PhD, Nikhil Munshi, MD, Kenneth C Anderson, MD, Steven P Treon, MDPhDFRCP

Blood (2017) 130 (Supplement 1): 3812.

https://doi.org/10.1182/blood.V130.Suppl_1.3812.3812

Published: 2017

Journal Articles

MYD88 Mutation Status Impacts Overall Survival and Risk of Histological Transformation in Waldenstrom's Macroglobulinemia

Steven P Treon, MDPhDFRCP, Zachary Hunter, PhD, Joshua Gustine, Kirsten Meid, MPH, Lian Xu, Xia Liu, MD, Guang Yang, PhD, Manit Munshi, MS, Robert Manning, Nickolas Tsakmaklis, BA, Maria Demos, BS, Amanda Kofides, BS, Maria Luisa Guerrera, MD, Jiaji Chen, BS, Gloria Chan, MS, Christopher Patterson, MAcc, Toni Dubeau, NP, Patricia Severns, NP, Jorge J. Castillo, MD

Blood (2017) 130 (Supplement 1): 4006.

https://doi.org/10.1182/blood.V130.Suppl_1.4006.4006

Published: 2017

Journal Articles

Prospective Phase II Study of Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenström Macroglobulinemia

Jorge J. Castillo, MD, Kirsten Meid, MPH, Joshua Gustine, Toni Dubeau, NP, Patricia Severns, NP, Steven P Treon, MDPhDFRCP

Blood (2017) 130 (Supplement 1): 1487.

https://doi.org/10.1182/blood.V130.Suppl_1.1487.1487

Published: 2017

Journal Articles

Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide-Based Therapy in Frontline Waldenstrom Macroglobulinemia

Jorge J. Castillo, MD, Joshua Gustine, Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Steven P Treon, MDPhDFRCP

Blood (2017) 130 (Supplement 1): 1488.

https://doi.org/10.1182/blood.V130.Suppl_1.1488.1488

Published: 2017

Journal Articles

Survival Rates and Clinical Characteristics of Young Patients with Waldenström Macroglobulinemia

Amaara Babwah, MS, Joshua Gustine, Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Steven P Treon, MDPhDFRCP, Jorge J. Castillo, MD

Blood (2017) 130 (Supplement 1): 4043.

https://doi.org/10.1182/blood.V130.Suppl_1.4043.4043

Published: 2017

Journal Articles

Differential Diagnosis of Suspected MYD88 Wild-Type Waldenstrom's Macroglobulinemia Includes Other Malignant and Non-Malignant IgM Secreting Entities, Including Frequent Cases of IgM Myeloma

Blood (2017) 130 (Supplement 1): 4385.

https://doi.org/10.1182/blood.V130.Suppl_1.4385.4385

Published: 2017

Journal Articles

Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated Waldenström Macroglobulinemia

Joshua Gustine, Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Steven P Treon, MDPhDFRCP, Jorge J. Castillo, MD

Blood (2017) 130 (Supplement 1): 4051.

https://doi.org/10.1182/blood.V130.Suppl_1.4051.4051

Published: 2017

Journal Articles

Acquired Von Willebrand Disease in Patients with Waldenström Macroglobulinemia

Jorge J. Castillo, MD, Joshua Gustine, Kirsten Meid, MPH, Toni Dubeau, NP, Patricia Severns, NP, Steven P Treon, MDPhDFRCP

Blood (2017) 130 (Supplement 1): 1088.

https://doi.org/10.1182/blood.V130.Suppl_1.1088.1088

Published: 2017

NARROW

BTK Cys481Ser drives ibrutinib resistance via ERK1/2 and protects BTK wild-type MYD88-mutated cells by a paracrine mechanism

The Genomic Landscape of MYD88 Wild-Type WaldenströM's Macroglobulinemia Ischaracterized By Somatic Mutations in TBL1XR1, the CBM Complex, and NFKB2

Patient-Reported Symptoms during Ibrutinib Holds: A Withdrawal Syndrome

Ibrutinib Discontinuation in Waldenström Macroglobulinemia: Etiologies, Outcomes, and IgM Rebound

Long-Term Follow-up of Previously Treated Patients Who Received Ibrutinib for Symptomatic Waldenstrom's Macroglobulinemia: Update of Pivotal Clinical Trial

Ibrutinib Is Highly Active As First Line Therapy in Symptomatic Waldenstrom's Macroglobulinemia

Long-Term Follow-up of a Prospective Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in Waldenstrom's Macroglobulinemia

TP53 mutations Are Associated with Mutated MYD88 and CXCR4, and Confer an Adverse Outcome in Waldenström Macroglobulinemia

Abnormal Splicing Patterns and Novel Intron Retentions Affect Genes Regulating Splicing, NF-Kb, ERK1/2, and TP53 in Waldenstrom's Macroglobulinemia

MYD88 Mutation Status Impacts Overall Survival and Risk of Histological Transformation in Waldenstrom's Macroglobulinemia

Prospective Phase II Study of Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenström Macroglobulinemia

Bendamustine and Bortezomib-Containing Regimens Produce Higher Response Rates and More Durable Responses Versus Cyclophosphamide-Based Therapy in Frontline Waldenstrom Macroglobulinemia

Survival Rates and Clinical Characteristics of Young Patients with Waldenström Macroglobulinemia

Differential Diagnosis of Suspected MYD88 Wild-Type Waldenstrom's Macroglobulinemia Includes Other Malignant and Non-Malignant IgM Secreting Entities, Including Frequent Cases of IgM Myeloma

Impact of Ibrutinib Dose Intensity on Patient Outcomes in Previously Treated Waldenström Macroglobulinemia

Acquired Von Willebrand Disease in Patients with Waldenström Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only